Introduction
The long-standing unmet need of the osteoporosis market has been for improved
adherence to treatment. Two pipeline products, Amgen' s Denosumab and Novartis'
Aclasta (zoledronate), have answered this demand with intermittent dosing
schedules and consequently are expected to generate blockbuster revenues. This
will rejuvenate the market which is otherwise stalling under multiple patent
expiries.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
osteoporosis
- Overview of drugs in late- and early-stage clinical development; with
analysis of key companies involved in the R&D pipeline
- Detailed profiles of key compounds in development for use in osteoporosis,
with forecasts of drug revenues to 2016
- Review of the key strategies adopted by current market players
Report Highlights
Despite the genericization of the market leader Fosamax and patent expiries on
other key brands, pipeline products are still viable. Datamonitor expects
pipeline products to swell the total market value 4.4% between 2007 and 2016
to $10.9 billion.
Products that offer intermittent dosing schedules are highly desirable in the
osteoporosis market and can generate blockbuster revenues. Such therapies
answer the demand from patients and physicians for more convenient delivery
mechanisms that increase compliance and ultimately improve treatment outcome.
Although bisphosphonates are the mainstay of osteoporosis treatment, there is
potential for new and innovative products to gain market share. Those that
suit niche populations, such as Chugai' s ED-71 which finds favor as a vitamin D
analogue in Japan, will be able to fight generic competition.
Reasons to Purchase
- Understand clinical and environmental unmet needs in the osteoporosis
market based on key opinion leader comments
- Benchmark key late-stage pipeline products against the current market
leader and class comparator
- Assess the global (US, Japan, five major EU) sales forecasts of key
late-stage pipeline drugs; and examine their clinical and commercial potential
| 
View Cart
